Ren Shen Yang Rong Tang for Fatigue in Cancer Survivors
This open-label, prospective, phase
I/II trial was performed to establish the safety and efficacy of Traditional Chinese
Medicine (TCM) herbal products for treating non-anemia-related fatigue in
patients with cancer. Although this practice is widespread in China, it has not
been confirmed in a prospective clinical study. Thirty-three patients who had
completed cancer treatment, had stable disease and no anemia, and reported
moderate to severe fatigue (rated ≥4 on a 0-10 scale) were enrolled in a TCM
outpatient clinic. Patients took Ren Shen Yangrong Tang (RSYRT) decoction, a
soup containing 12 TCM herbs, twice a day for 6 weeks. RSYRT aims to correct qi
deficiency. Fatigue was assessed before and after RSYRT therapy, which all
patients completed. No discomfort or toxicity was observed. Before the study,
all patients had had fatigue for at least 4 months. Fatigue severity decreased
significantly from before therapy to 6 weeks after therapy: from 7.06 to 3.30
on a 0-10 scale (p<0.001). Fatigue category (mild, moderate, severe) shifted
significantly (p=0.024): Of 22 patients with severe fatigue (rated ≥7) before
therapy, 11 had mild fatigue and 11 had moderate fatigue after TCM treatment.
The time-to-fatigue-alleviation was 2-3 weeks. RSYRT therapy was safe and was
associated with fatigue improvement in nonanemic cancer survivors, consistent
with historical TCM clinical practice experience. Because of a possible placebo
effect in this open-label study, decoction RSYRT warrants further study in
randomized clinical trials to confirm its effectiveness for managing moderate
to severe fatigue.
Source: Xu Y,
Chen Y,
Li P,
Wang XS.
Ren Shen
Yangrong Tang for Fatigue in Cancer Survivors: A Phase I/II Open-Label Study. J Altern
Complement Med. 2015 May;21(5):281-7.
No comments:
Post a Comment